☰

Chih-Chun Chang - Publications

Affiliations: 
2017-2019 National Tsing Hua University, Hsinchu City, Taiwan, ROC 
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Wang LH, Chang CC, Cheng CY, Liang YJ, Pei D, Sun JT, Chen YL. MCRS1 Expression Regulates Tumor Activity and Affects Survival Probability of Patients with Gastric Cancer. Diagnostics (Basel, Switzerland). 12. PMID 35741311 DOI: 10.3390/diagnostics12061502  0.307
2021 Huang CP, Liu LC, Chang CC, Wu CC, Shyr CR. Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. Cancer Letters. PMID 35902043 DOI: 10.1016/j.canlet.2021.10.044  0.416
2021 Song JS, Chang CC, Wu CH, Dinh TK, Jan JJ, Huang KW, Chou MC, Shiue TY, Yeh KC, Ke YY, Yeh TK, Ta YN, Lee CJ, Huang JK, Sung YC, et al. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33753481 DOI: 10.1073/pnas.2015433118  0.801
2020 Chang CC, Dinh TK, Lee YA, Wang FN, Sung YC, Yu PL, Chiu SC, Shih YC, Wu CY, Huang YD, Wang J, Lu TT, Wan D, Chen Y. Nanoparticle Delivery of MnO2 and Anti-angiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma. Acs Applied Materials & Interfaces. PMID 32865389 DOI: 10.1021/Acsami.0C08473  0.771
2020 Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, Huang YT, Sung YC, Chiang CC, Huang RL, Lin CC, Dinh TK, Huang HC, Shih YC, Alson D, et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Science Advances. 6: eaax5032. PMID 31998834 DOI: 10.1126/Sciadv.Aax5032  0.603
2019 Sung YC, Jin PR, Chu LA, Hsu FF, Wang MR, Chang CC, Chiou SJ, Qiu JT, Gao DY, Lin CC, Chen YS, Hsu YC, Wang J, Wang FN, Yu PL, et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nature Nanotechnology. PMID 31740794 DOI: 10.1038/S41565-019-0570-3  0.735
2018 Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 8: 894-905. PMID 29463989 DOI: 10.7150/Thno.21168  0.696
2017 Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports. 7: 44123. PMID 28276530 DOI: 10.1038/Srep44123  0.824
2015 Gao DY, Lin TT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 67: 194-203. PMID 26218745 DOI: 10.1016/J.Biomaterials.2015.07.035  0.832
Show low-probability matches.